Topic: metabolic syndrome
When the gene-editing technology CRISPR-Cas9 to inhibit the gene FABP4 in mice, the animals lost 20% of their body weight.
Targeting fatty lipids known as ceramides reverses insulin resistance and fatty liver, scientists from the University of Utah and Merck found.
Comet Therapeutics unveiled itself with $28.5 million in series A financing and biopharma veteran David De Graaf at the helm.
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
A new study suggests that some gut immune cells modulate the process by which the body either stores ingested food as fat or uses it for energy.
In mouse models of obesity, the naturally occurring protein FGFBP3 drastically reduced fat mass.
Targeting a protein called sarcolipin could prompt the body to burn more fat, researchers suggest in a new study.
Scientists at American University have discovered a potential method for treating obesity.
California researchers have gained insight into how a 30-year-old asthma drug called amlexanox helps burn calories—and it all ties into inflammation.
The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.